+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users



Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users



Annals of Neurology 40(3): 428-439



Depletion of striatal dopamine (DA) has been hypothesized to explain some of the neurological and psychiatric complications of chronic use of cocaine, including increased risk for neuroleptic-precipitated movement disorders. We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users. Mean DA levels were normal in the putamen, the motor component of the striatum; however 4 of the 12 subjects had DA values below the lower limit of the control range. DA concentrations were significantly reduced in the caudate head (head, -33%; tail, -39%) with a trend for reduction in nucleus accumbens (-27%). Striatal DAT protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas DAT determined by [3H]WIN 35,428 binding was normal. In conclusion, our data suggest that chronic cocaine use is associated with modestly reduced levels of striatal DA and the DA transporter in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009462877

Download citation: RISBibTeXText

PMID: 8797532

DOI: 10.1002/ana.410400312


Related references

Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Molecular Pharmacology 47(2): 368-373, 1995

The Vesicular Monoamine Transporter, in Contrast to the Dopamine Transporter, Is Not Altered by Chronic Cocaine Self-Administration in the Rat. The Journal of Neuroscience 16(10): 3507-3510, 1996

The vesicular monoamine transporter, in contrast to the dopamine transporter, is not regulated following chronic cocaine self-administration. Society for Neuroscience Abstracts 21(1-3): 1382, 1995

The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. Journal of Neuroscience 16(10): 3507-3510, 1996

Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61(7): 573-576, 2007

Age-related decreases in striatal dopamine transporter and vesicular monoamine transporter binding sites in alcoholics. Alcoholism Clinical & Experimental Research 22(3 ABSTR Suppl. ): 48A, 1998

HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. Journal of Neuroimmune Pharmacology 7(3): 629-639, 2012

Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. Plos one 7(11): E49483, 2012

Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. Journal of Neurochemistry 111(5): 1202-1212, 2009

Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. American Journal of Psychiatry 160(1): 47-55, 2003

Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. European Journal of Pharmacology 504(1-2): 27-32, 2004

Substitution of carboxyl tail of bovine dopamine transporter for human dopamine transporter attenuates substrate transport and cocaine binding in human dopamine transporter. Society for Neuroscience Abstracts 23(1-2): 407, 1997

Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. European Journal of Pharmacology 389(1): 59-65, 2000

The inhibition of vesicular monoamine transporter 2 partially reduces the toxicity of 6-hydroxydopamine on nigro-striatal dopamine neurons. Society for Neuroscience Abstracts 27(1): 1148, 2001

Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. Journal of Neurochemistry 85(4): 898-910, 2003